J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Clinical trials update from the European Society of Cardiology Heart Failure meeting 2011: TEHAF, WHICH, CARVIVA, and atrial fibrillation in GISSI-HF and EMPHASIS-HF.
TL;DR: Results from CARVIVA‐HF suggest that ivabradine alone or in combination with carvedilol is safe and effective for improving exercise capacity and quality of life in HF patients on optimized angiotensin‐converting enzyme inhibitor therapy.
Journal ArticleDOI
Clinical Trials Report: Cardiovascular & Renal: Ongoing and planned clinical trials in chronic heart failure and left ventricular dysfunction
TL;DR: This report reviews current therapies for CHF, the rationale behind the development of new agents for this indication, and the ongoing and planned clinical trials for the treatment of CHF and left ventricular dysfunction.
Journal ArticleDOI
Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF.
Masatake Kobayashi,Adriaan A. Voors,Nicolas Girerd,Maxime Billotte,Stefan D. Anker,John G.F. Cleland,Chim C. Lang,Leong L. Ng,Dirk J. van Veldhuisen,Kenneth Dickstein,M. Metra,Kevin Duarte,Patrick Rossignol,Faiez Zannad,João Pedro Ferreira +14 more
TL;DR: In BIOSTAT-CHF, patients with HF of an ischemic etiology, and those with worsening HF precipitated by renal failure, had the highest rates of death and HF hospitalization, but still benefited equally from treatment up-titration.
Journal ArticleDOI
Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation
David J. Cohen,Kaijun Wang,Elizabeth A. Magnuson,Robert Smith,Mark C. Petrie,Mamta H. Buch,W. Abraham,JoAnn Lindenfeld,Michael J. Mack,Gregg W. Stone,John G.F. Cleland +10 more
TL;DR: For patients with HFrEF and severe secondary mitral regurgitation similar to those enrolled in COAPT, TMVr increases life expectancy and quality-adjusted life expectancy compared with GRMT at an ICER that represents good value from an NHS perspective.
Journal ArticleDOI
Does cirrhotic cardiomyopathy exist? 50 years of uncertainty
Pierpaolo Pellicori,Concetta Torromeo,Angela Calicchia,A. Ruffa,Martina Di Iorio,John G.F. Cleland,Manuela Merli +6 more
TL;DR: Cardiac dysfunction in patients with cirrhosis can be attributed to concomitant diseases such as hypertension, ischaemic heart disease or excess alcohol consumption in many patients, and further research is required to identify the existence, origin and importance of abnormal cardiac function due specifically to liver disease.